Viropro and CoreRx Enter into a Reciprocal Referral Agreement
CoreRx,Inc. and Viropro, Inc. announced that the two companies have entered into a Reciprocal Referral Agreement. The Agreement will benefit both companies' existing and potential clients with diverse product pipelines by combining CoreRx's problem-solving and formulation/processing expertise in small molecules with Viropro's reputation in the development and manufacturing of biopharmaceutical drugs. Cynthia Tsai, Chairperson and CEO of Viropro, Inc., said, "The agreement is another important step in Viropro's push to build a global network committed to delivering solutions to advance new medicines. It will also leverage Viropro's expertise to provide clients with optimized solutions to their biopharmaceutical development challenges."
distributed by